

Peter C Black

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3793733/peter-c-black-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

366
papers

9,034
citations

50
h-index

82
g-index

462
ext. papers

11,460
ext. citations

3.8
avg. IF

6.05
L-index

#	Paper	IF	Citations
366	State-of-the-Art and Future Role of Molecular Biomarkers for Patient Selection 2022 , 91-107		
365	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.. <i>European Urology Oncology</i> , 2022 ,	6.7	4
364	Towards targeted ultrasound-guided prostate biopsy by incorporating model and label uncertainty in cancer detection. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2021 , 17, 121	3.9	1
363	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021 , 128, 79-87	5.6	7
362	Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) program. <i>Canadian Urological Association Journal</i> , 2021 , 15, 33-39	1.2	2
361	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2021 , 15, E123-E126	1.2	
360	Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment. <i>Bladder Cancer</i> , 2021 , 7, 1-11	1	0
359	Characterizing The Uncertainty Of Label Noise In Systematic Ultrasound-Guided Prostate Biopsy 2021 ,		1
358	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. <i>Canadian Urological Association Journal</i> , 2021 , 15, E424-E460	1.2	1
357	Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4541-4541	2.2	2
356	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 301.e17-301.e28	2.8	1
355	Current Perioperative Therapy for Muscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 495-511	3.1	1
354	Heterogeneity in Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021 , 27, 5123-5130	12.9	13
353	Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>Eur Urol</i> 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based	10.2	
352	Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1399-1408	6.7	1
351	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021 , 79, 16-19	10.2	15
350	Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 1569-1575	4	1

349	Setting the stage for bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 209-212	2.8	2
348	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021 , 127, 528-537	5.6	1
347	Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. <i>BJU International</i> , 2021 , 127, 473-485	5.6	1
346	Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211039052	5.4	2
345	Sex- and age-related differences in the distribution of bladder cancer metastases. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 976-983	2.8	2
344	Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy. <i>Nature Communications</i> , 2021 , 12, 4833	17.4	0
343	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021 , 80, 149-159	10.2	5
342	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021 , 39, 4345-4354	4	2
341	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 498.e1-498.e11	2.8	0
340	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. <i>Cell Reports Medicine</i> , 2021 , 2, 100382	18	1
339	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 528-547	2.8	
338	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021 , 12, 184	17.4	25
337	Second-opinion reads in prostate MRI: added value of subspecialty interpretation and review at multidisciplinary rounds.. <i>Abdominal Radiology</i> , 2021 , 47, 827	3	1
336	Variant histology in bladder cancer: diagnostic and clinical implications.. <i>Translational Cancer Research</i> , 2020 , 9, 6565-6575	0.3	4
335	Multiple instance learning combined with label invariant synthetic data for guiding systematic prostate biopsy: a feasibility study. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020 , 15, 1023-1031	3.9	5
334	Evaluation of a marker-less, intra-operative, augmented reality guidance system for robot-assisted laparoscopic radical prostatectomy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020 , 15, 1225-1233	3.9	6
333	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 701-710	10.2	66
332	Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with Dysfunction. <i>Clinical Cancer Research</i> , 2020 , 26, 2065-2079	12.9	32

331	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020 , 14, E373-E382	1.2	3
330	Genomic Subtyping in Bladder Cancer. <i>Current Urology Reports</i> , 2020 , 21, 9	2.9	9
329	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guërin. <i>European Urology</i> , 2020 , 78, 387-399	10.2	11
328	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020 , 6, 363-392	1	0
327	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient's undergoing urologic oncology surgery: a systematic review. <i>World Journal of Urology</i> , 2020 , 1	4	9
326	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020 , 78, 719-730	10.2	18
325	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 639.e1-639.e9	2.8	7
324	Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. <i>Pathology Research and Practice</i> , 2020 , 216, 152822	3.4	2
323	Emerging intravesical therapies for the management of bacillus Calmette-Guërin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward. <i>Canadian Urological Association Journal</i> , 2020 , 14, 204-213	1.2	6
322	Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1760-1762	2.2	5
321	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020 , 3, 420-423	6.7	11
320	Re: Clinical Efficacy and Biomarker Analysis of Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial. <i>European Urology</i> , 2020 , 77, 652-653	10.2	
319	Radical cystectomy: a review of techniques, developments and controversies. <i>Translational Andrology and Urology</i> , 2020 , 9, 3073-3081	2.3	5
318	Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis. <i>Current Molecular Pharmacology</i> , 2020 , 13, 150-172	3.7	5
317	Building a Canadian Translational Bladder Cancer Research Network. <i>Canadian Urological Association Journal</i> , 2020 , 14, E475-E481	1.2	
316	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , 2020 , 73, 407-415	0.9	
315	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020 , 38, 1959-1968	4	12
314	A partial augmented reality system with live ultrasound and registered preoperative MRI for guiding robot-assisted radical prostatectomy. <i>Medical Image Analysis</i> , 2020 , 60, 101588	15.4	16

313	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 3.e17-3.e27	2.8	15
312	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 262-268	2.8	9
311	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
310	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 882-891	12.9	39
309	Re: Aurŕie Kamoun, Aurŕien de Reyniŕ, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2020;77:420-33: A Statement from the International Bladder Cancer Network. <i>European Urology</i> , 2020 , 77, e105-e106	10.2	12
308	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. <i>Computers in Biology and Medicine</i> , 2020 , 127, 104053	7	1
307	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020 , 78, 893-906	10.2	35
306	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020 , 26, 2773-2781	2.6	4
305	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020 , 6, 65	6.9	2
304	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2210-2220	6.1	5
303	Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. <i>European Urology Oncology</i> , 2020 , 3, 622-630	6.7	17
302	Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2020 , 14, E115-E125	1.2	1
301	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 858-866	2.8	8
300	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020 , 77, 420-433	10.2	309
299	Deep Learning-Based Gleason Grading of Prostate Cancer From Histopathology Images-Role of Multiscale Decision Aggregation and Data Augmentation. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020 , 24, 1413-1426	7.2	42
298	Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator. <i>World Journal of Urology</i> , 2020 , 38, 1215-1220	4	7
297	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3090-3098	2.2	44
296	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019 , 76, 59-68	10.2	63

295	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019 , 318-327	1.2	5
294	Molecular landscape of carcinoma invading bladder muscle: does patient age matter?. <i>BJU International</i> , 2019 , 124, 719-721	5.6	3
293	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. <i>European Urology</i> , 2019 , 76, 200-206	10.2	24
292	Comparison of Artificial Intelligence Techniques to Evaluate Performance of a Classifier for Automatic Grading of Prostate Cancer From Digitized Histopathologic Images. <i>JAMA Network Open</i> , 2019 , 2, e190442	10.4	48
291	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3908-3920	12.9	42
290	Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?. <i>European Urology Oncology</i> , 2019 , 2, 597-602	6.7	10
289	Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?. <i>European Urology Oncology</i> , 2019 , 2, 723-729	6.7	1
288	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019 , 11, 60	14.4	21
287	Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16036-e16036	2.2	1
286	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 457-457	2.2	2
285	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 526-526	2.2	1
284	The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. <i>Human Gene Therapy</i> , 2019 , 30, 44-56	4.8	4
283	Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016. <i>Journal of Urology</i> , 2019 , 201, 893-901	2.5	42
282	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. <i>Journal of Urology</i> , 2019 , 202, 49-56	2.5	13
281	Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019 , 202, 1111-1119	2.5	17
280	Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy. <i>Journal of Urology</i> , 2019 , 202, 1001-1007	2.5	13
279	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019 , 2, 119-125	6.7	13
278	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 1600-1610	6.7	15

277	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5082-5093	12.9	50
276	Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study. <i>NMR in Biomedicine</i> , 2019 , 32, e4048-4	4.4	8
275	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019 , 75, 667-675	10.2	74
274	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2019 , 230-238	1.2	21
273	Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. <i>International Journal of Cancer</i> , 2018 , 143, 1764-1773	7.5	20
272	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018 , 122, 434-440	5.6	7
271	Unravelling disparate roles of NOTCH in bladder cancer. <i>Nature Reviews Urology</i> , 2018 , 15, 345-357	5.5	29
270	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. <i>Journal of Urology</i> , 2018 , 199, 1129-1142	2.5	28
269	Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2018 , 199, 1452-1458	2.5	45
268	Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. <i>European Urology</i> , 2018 , 73, 899-907	10.2	36
267	Real-Time FEM-Based Registration of 3-D to 2.5-D Transrectal Ultrasound Images. <i>IEEE Transactions on Medical Imaging</i> , 2018 , 37, 1877-1886	11.7	10
266	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 342.e7-342.e14	2.8	5
265	Filling a True Unmet Need: A New Therapy for Nonmetastatic Castrate-resistant Prostate Cancer Commentary on: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>Urology</i> , 2018 , 116, 1-2	1.6	
264	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018 , 73, 738-748	10.2	77
263	Orthotopic Mouse Models of Urothelial Cancer. <i>Methods in Molecular Biology</i> , 2018 , 1655, 177-197	1.4	6
262	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2018 , 12, 243-251	1.2	5
261	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 429-440	1	5
260	Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>Urology</i> , 2018 , 121, 1-2	1.6	1

259	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018 , 12, E281-E297	1.2	6
258	Magnet Before the Needle Commentary on: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis (PRECISION Trial). <i>Urology</i> , 2018 , 118, 1-2	1.6	4
257	Outcomes of Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy of PI-RADS 3, 4, and 5 Lesions. <i>Canadian Association of Radiologists Journal</i> , 2018 , 69, 303-310	3.9	0
256	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018 , 1, 223-230	6.7	17
255	Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 569-569	2.2	2
254	S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS527-TPS527	2.2	6
253	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2018 , 12, 270-275	1.2	5
252	Apparent plasticity in the biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 433-433	2.2	
251	A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 440-440	2.2	
250	Patterns and predictors of attendance at a comprehensive, multi-disciplinary supportive care program for men with prostate cancer and their partners.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6-6	2.2	
249	Perspectives on the discovery of NOTCH2-specific inhibitors. <i>Chemical Biology and Drug Design</i> , 2018 , 91, 691-706	2.9	6
248	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. <i>World Journal of Urology</i> , 2018 , 36, 215-220	4	47
247	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 413-422	2.8	16
246	Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018 , 4, 512-521	5.1	8
245	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018 , 1, 91-100	6.7	34
244	New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. <i>Bladder Cancer</i> , 2018 , 4, 339-342	1	
243	Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 ,	2.8	19
242	Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation. <i>Urology Case Reports</i> , 2018 , 21, 89-91	0.5	1

241	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018 , 74, 784-795	10.2	265
240	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2746-2755	6.1	34
239	Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. <i>Medical Image Analysis</i> , 2018 , 50, 167-180	15.4	63
238	Current Clinical Trials in Non-muscle Invasive Bladder Cancer. <i>Current Urology Reports</i> , 2018 , 19, 101	2.9	20
237	A risk-stratified approach to the management of high-grade T1 bladder cancer. <i>Current Opinion in Urology</i> , 2018 , 28, 563-569	2.8	3
236	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 19-29	1	25
235	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. <i>Lab on A Chip</i> , 2018 , 18, 1736-1749	7.2	11
234	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2018 ,	1.2	7
233	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 328-334	2.8	16
232	Editorial Comment. <i>Journal of Urology</i> , 2017 , 197, 215	2.5	
231	Editorial Comment. <i>Journal of Urology</i> , 2017 , 197, 595	2.5	
230	Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy. <i>Urology</i> , 2017 , 105, 13	1.6	
229	MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology. <i>Journal of Magnetic Resonance Imaging</i> , 2017 , 46, 861-869	5.6	22
228	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , 2017 , 7, 42713	4.9	58
227	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 458.e1-458.e7	2.8	6
226	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017 , 72, 544-554	10.2	411
225	Luminal Water Imaging: A New MR Imaging T2 Mapping Technique for Prostate Cancer Diagnosis. <i>Radiology</i> , 2017 , 284, 451-459	20.5	42
224	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017 , 72, 142-150	10.2	29

223	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017 , 3, 1663-1672	13.4	138
222	Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>Urology</i> , 2017 , 106, 1-2	1.6	6
221	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017 , 35, 1729-1736	4	7
220	You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer: Commentary on: Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-reported Outcomes After 3 Years. <i>Urology</i> , 2017 , 107, 3-4	1.6	
219	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 689-695.e2	3.3	10
218	Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial. <i>Urology</i> , 2017 , 104, 7-8	1.6	1
217	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. <i>Journal of Endourology</i> , 2017 , 31, 645-650	2.7	7
216	Commentary on: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>Urology</i> , 2017 , 104, 5-6	1.6	
215	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. <i>Canadian Urological Association Journal</i> , 2017 , 11, 182-187	1.2	17
214	New research in bladder cancer, ASCO-GU 2017. <i>Canadian Urological Association Journal</i> , 2017 , 11, S160-S162	1.6	2
213	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017 , 11, 232-237	1.2	5
212	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	10
211	Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2017 , 24, 594-600	2.3	6
210	Identifying intermediate-risk candidates for active surveillance of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 605.e1-605.e8	2.8	13
209	Evasion of immunosurveillance by genomic alterations of PPAR α /RXR α in bladder cancer. <i>Nature Communications</i> , 2017 , 8, 103	17.4	66
208	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 6487-6497	12.9	81
207	Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer. <i>Urology</i> , 2017 , 109, 1-2	1.6	
206	Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma. <i>European Urology</i> , 2017 , 72, 653-654	1.2	2

205	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2017 , 24, 7-15	2.3	10
204	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , 2017 , 71, 545-557	10.2	46
203	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2017 , 197, 135-142	2.5	90
202	Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. <i>European Journal of Immunology</i> , 2017 , 47, 385-393	6.1	47
201	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. <i>CMAJ Open</i> , 2017 , 5, E834-E841	2.5	0
200	CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatment Strategy for Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 79-88	1	13
199	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 145-146	1	5
198	Evolving attitudes toward robotic surgery among Canadian urology residents. <i>Canadian Urological Association Journal</i> , 2017 , 11, E266-E270	1.2	2
197	Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2017 , 11, 173-181	1.2	6
196	S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4591-TPS4591	2.2	4
195	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 695-701	4	1
194	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016 , 195, 53-9	2.5	72
193	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016 , 196, 1627-1633	2.5	26
192	Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>European Urology</i> , 2016 , 70, 1076	10.2	
191	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e17-486.e23	2.8	19
190	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. <i>BJU International</i> , 2016 , 118, 855-863	3.6	48
189	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 486.e1-486.e7	2.8	25
188	Emerging role of checkpoint inhibition in localized bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 548-555	2.8	14

187	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 469-76	2.8	7
186	Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2016 , 22, 2981-92	12.9	60
185	Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma. <i>Urology</i> , 2016 , 89, 8-9	1.6	6
184	Pioglitazone: No Longer a Worry for Bladder Cancer?. <i>Urology</i> , 2016 , 91, 19-20	1.6	3
183	Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. <i>Urology</i> , 2016 , 89, 10-1	1.6	1
182	Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. <i>Eur Urol</i> 2015;68:399-405. <i>European Urology</i> , 2016 , 69, e35	10.2	4
181	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016 , 195, 886-93	2.5	59
180	Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 223-223	2.2	2
179	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 393-393	2.2	1
178	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. <i>Oncotarget</i> , 2016 , 7, 39980-39995	3.3	20
177	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. <i>Canadian Urological Association Journal</i> , 2016 , 10, 90-4	1.2	5
176	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016 , 10, 74-80	1.2	39
175	Successful implementation of a disease-specific survivorship program for men with prostate cancer (PC) and their partners.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 31-31	2.2	
174	Implementation of a disease specific survivorship program for men with prostate cancer and their partners.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21569-e21569	2.2	
173	Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23075-e23075	2.2	
172	Post-radiation epithelioid angiosarcoma of the urinary bladder and prostate. <i>Canadian Urological Association Journal</i> , 2016 , 10, E197-E200	1.2	10
171	Next generation biomarkers in prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2016 , 21, 328-42	2.8	13
170	Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets. <i>Small</i> , 2016 , 12, 1909-19	11	91

169	Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. <i>BMC Research Notes</i> , 2016 , 9, 454	2.3	1
168	Building the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Urology</i> , 2016 , 94, 1-2	1.6	3
167	PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI). <i>Journal of Urology</i> , 2016 , 195,	2.5	2
166	Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. <i>Urology</i> , 2016 , 94, 154-60	1.6	45
165	Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 41-8	4	15
164	Comparison of Magnetic Resonance/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. <i>Urology</i> , 2016 , 89, 6-7	1.6	
163	Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer. <i>JAMA Oncology</i> , 2016 , 2, 855-6	13.4	8
162	Chemical vs Surgical ADT in Metastatic Prostate Cancer: A Comparison of Side Effects. Commentary on Comparison of Gonadotropin-releasing Hormone Agonists and Orchiectomy: Effects of Androgen Deprivation Therapy. <i>Urology</i> , 2016 , 93, 3-4	1.6	5
161	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016 , 196, 1036-41	2.5	24
160	Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 483.e9-483.e16	2.8	21
159	Retraction notice to "Narrowing the Cystoscopy Gap": <i>Eur Urol</i> 67 (2015) 609-610. <i>European Urology</i> , 2016 , 70, e24	10.2	
158	Taking the next step-Advancing bladder cancer management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 435-6	2.8	1
157	Predicting occult lymph node-positive disease at the time of radical cystectomy: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016 , 68, 112-24	4.4	5
156	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015 , 68, 238-53	10.2	168
155	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , 2015 , 194, 1120-31	2.5	45
154	Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 66.e13-9	2.8	4
153	Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 165.e1-7	2.8	27
152	Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps. <i>Lab on A Chip</i> , 2015 , 15, 2278-86	7.2	64

151	Intraoperative registered transrectal ultrasound guidance for robot-assisted laparoscopic radical prostatectomy. <i>Journal of Urology</i> , 2015 , 193, 302-12	2.5	24
150	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015 , 116, 72-8	5.6	26
149	Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. <i>Journal of Clinical Oncology</i> , 2015 , 33, 51-7	2.2	193
148	MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2015 , 193,	2.5	1
147	Malakoplakia of the prostate masquerading as locally advanced prostate cancer on mpMRI. <i>Canadian Urological Association Journal</i> , 2015 , 9, E910-2	1.2	4
146	Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2015 , 9, 397-402	1.2	5
145	Surgical management of stage T1 renal tumours at Canadian academic centres. <i>Canadian Urological Association Journal</i> , 2015 , 9, 99-106	1.2	7
144	Statistical Biomechanical Surface Registration: Application to MR-TRUS Fusion for Prostate Interventions. <i>IEEE Transactions on Medical Imaging</i> , 2015 , 34, 2535-49	11.7	16
143	Multimodal classification of prostate tissue: a feasibility study on combining multiparametric MRI and ultrasound 2015 ,		2
142	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2015 , 67, 241-9	10.2	178
141	Conditional survival after radical nephroureterectomy for upper tract carcinoma. <i>European Urology</i> , 2015 , 67, 803-12	10.2	54
140	Reply: To PMID 25623709. <i>Urology</i> , 2015 , 85, 429	1.6	
139	Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer. <i>Urology</i> , 2015 , 85, 423-8	1.6	43
138	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. <i>BJU International</i> , 2015 , 116, 556-67	5.6	14
137	Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. <i>European Urology</i> , 2015 , 67, 876-88	10.2	50
136	Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4512-4512	2.2	4
135	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. <i>Oncotarget</i> , 2015 , 6, 21522-32	3.3	30
134	A standardized protocol for identifying and counting lymph nodes harvested by pelvic lymph node dissection at the time of radical cystectomy. <i>Canadian Urological Association Journal</i> , 2015 , 9, 337-42	1.2	3

133	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2015 , 9, E690-704	1.2	53
132	A System for MR-Ultrasound Guidance during Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Lecture Notes in Computer Science</i> , 2015 , 497-504	0.9	6
131	A 2D-3D Registration Framework for Freehand TRUS-Guided Prostate Biopsy. <i>Lecture Notes in Computer Science</i> , 2015 , 272-279	0.9	6
130	The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 480-480	2.2	
129	The impact of time to metastasis on survival in treatment-naïve prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 212-212	2.2	
128	Patient perceptions of ovarian cancer, its treatment, and its impact: A qualitative interview study in three European countries.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16550-e16550	2.2	
127	Canadian guidelines for SRMs: How Canadian are they?. <i>Canadian Urological Association Journal</i> , 2015 , 9, 163-213	1.2	
126	Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014 , 11, 220-30	5.5	34
125	Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. <i>Cancer</i> , 2014 , 120, 2424-31	6.4	12
124	Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1051-60	2.8	15
123	Radical prostatectomy trumps watchful waiting in early prostate cancer. Commentary on: Radical prostatectomy or watchful waiting in early prostate cancer. <i>Urology</i> , 2014 , 84, 253-4	1.6	2
122	A new way of thinking about bladder cancer. <i>Urology</i> , 2014 , 84, 1265-6	1.6	
121	MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2014 , 191,	2.5	1
120	Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. <i>European Urology</i> , 2014 , 66, 361-70	10.2	94
119	Prostate-specific Antigen Testing: Men's Responses to 2012 Recommendation Against Screening. <i>Urology</i> , 2014 , 83, 4-5	1.6	1
118	Renovascular hypertension after laparoscopic partial nephrectomy. <i>Journal of Urology</i> , 2014 , 191, 1418-20	5	2
117	MP28-14 TARGETING HER2 WITH TRASTUZUMAB-DM1 (T-DM1) IN HER2-OVEREXPRESSING BLADDER CANCER. <i>Journal of Urology</i> , 2014 , 191,	2.5	3
116	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 441-8	2.8	23

115	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 839-45	2.8	35
114	Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. <i>Journal of Urology</i> , 2014 , 192, 1673-8	2.5	50
113	Motion and deformation compensation for freehand prostate biopsies 2014 ,		1
112	Morphological differences between circulating tumor cells from prostate cancer patients and cultured prostate cancer cells. <i>PLoS ONE</i> , 2014 , 9, e85264	3.7	104
111	Minimally invasive establishment of murine orthotopic bladder xenografts. <i>Journal of Visualized Experiments</i> , 2014 , e51123	1.6	9
110	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. <i>Canadian Urological Association Journal</i> , 2014 , 8, E398-412	1.2	25
109	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014 , 8, E845-52	1.2	29
108	DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2014 , 192, 1842-8	2.5	12
107	Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. <i>BJU International</i> , 2014 , 113, E28-33	5.6	14
106	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <i>International Journal of Cancer</i> , 2014 , 135, 939-47	7.5	31
105	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014 , 8, 309-16	1.2	12
104	Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	36
103	Re: Gbter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? <i>Eur Urol</i> 2013;64:355-7. <i>European Urology</i> , 2014 , 65, e8-9	10.2	2
102	Underutilization of local salvage therapy after radiation therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 701-6	2.8	63
101	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e17-24	2.8	39
100	Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. <i>Lab on A Chip</i> , 2014 , 14, 32-44	7.2	145
99	Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 298-298	2.2	3
98	NOTCH2 inhibition on tumor growth and metastasis in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 315-315	2.2	1

97	Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 420-420	2.2	1
96	Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 434-434	2.2	
95	2130 VALIDATION OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH HIGH RISK PATHOLOGICAL FEATURES POST-PROSTATECTOMY. <i>Journal of Urology</i> , 2013 , 189,	2.5	1
94	Commentary on: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Urology</i> , 2013 , 82, 278-9	1.6	
93	Demographic analysis of randomized controlled trials in bladder cancer. <i>BJU International</i> , 2013 , 111, 419-26	5.6	4
92	A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. <i>Journal of Urology</i> , 2013 , 189, 1326-31	2.5	78
91	Commentary on: Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>Urology</i> , 2013 , 81, 7-8	1.6	2
90	594 SPECIFIC INHIBITION OF NOTCH-2 AS A NOVEL THERAPY FOR INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2013 , 189,	2.5	1
89	Intermittent Versus Continuous Androgen Deprivation in Prostate Cancer. <i>Urology</i> , 2013 , 82, 985-986	1.6	
88	Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. <i>Journal of Urology</i> , 2013 , 190, 1404-9	2.5	24
87	Commentary on: Intermittent androgen suppression for rising PSA level after radiotherapy. <i>Urology</i> , 2013 , 81, 473-4	1.6	
86	2239 CLINICAL AND GENOMIC ANALYSIS OF METASTATIC DISEASE PROGRESSION IN A BACKGROUND OF BIOCHEMICAL RECURRENCE. <i>Journal of Urology</i> , 2013 , 189,	2.5	1
85	Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Urology</i> , 2013 , 64, 518-9	10.2	1
84	Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. <i>BJU International</i> , 2013 , 111, 946-53	5.6	71
83	Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. <i>Urology</i> , 2013 , 81, 1121-1122	1.6	
82	Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. <i>Journal of Urology</i> , 2013 , 190, 2047-53	2.5	244
81	Penile carcinoma: lessons learned from vulvar carcinoma. <i>Journal of Urology</i> , 2013 , 189, 17-24	2.5	24
80	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1161-5	2.8	30

79	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. <i>BJU International</i> , 2013 , 112, 791-7	5.6	38
78	Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. <i>Journal of Oncology Practice</i> , 2013 , 9, e262-7	3.1	31
77	Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , 2013 , 7, 312-8	1.2	17
76	Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013 , 7, 306-11	1.2	6
75	Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. <i>Canadian Urological Association Journal</i> , 2013 , 7, 238-43	1.2	6
74	Highly selective biomechanical separation of cancer cells from leukocytes using microfluidic ratchets and hydrodynamic concentrator. <i>Biomicrofluidics</i> , 2013 , 7, 34114	3.2	42
73	Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1245-54	6.1	65
72	Three primary testicular tumours: Trials and tribulations of testicular preservation. <i>Canadian Urological Association Journal</i> , 2013 , 7, E630-3	1.2	4
71	Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). <i>Canadian Urological Association Journal</i> , 2013 , 7, E44-56	1.2	32
70	Double jeopardy? Renal-sparing management of simultaneous ipsilateral renal cell carcinoma and urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2013 , 7, E508-10	1.2	2
69	Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. <i>PLoS ONE</i> , 2013 , 8, e66855	3.7	406
68	Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. <i>PLoS ONE</i> , 2013 , 8, e57284	3.7	55
67	Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. <i>PLoS ONE</i> , 2013 , 8, e59536	3.7	40
66	Utilization of local salvage therapy after primary radiotherapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 231-231	2.2	
65	Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 36-36	2.2	
64	Commentary on: Radical prostatectomy versus observation for localized prostate cancer. <i>Urology</i> , 2012 , 80, 1181-2	1.6	1
63	The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. <i>Urology</i> , 2012 , 79, 840-5	1.6	42
62	1080 A PROSPECTIVE RANDOMIZED TRIAL OF POVIDONE-IODINE PROPHYLACTIC CLEANSING OF THE RECTUM PRIOR TO TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY. <i>Journal of Urology</i> , 2012 , 187,	2.5	1

61	Detection of bladder cancer using proteomic profiling of urine sediments. <i>PLoS ONE</i> , 2012 , 7, e42452	3.7	8
60	Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. <i>Frontiers in Genetics</i> , 2012 , 3, 23	4.5	16
59	Status of robotic-assisted surgery among Canadian urology residents. <i>Canadian Urological Association Journal</i> , 2012 , 6, 160-7	1.2	11
58	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 90-90	2.2	1
57	Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 175-175	2.2	3
56	A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 286-286	2.2	3
55	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012 , 6, 455-62	1.2	5
54	485 MULTI-INSTITUTIONAL QUALITY OF CARE INITIATIVE FOR NON-METASTATIC MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER: PHASE 1. <i>Journal of Urology</i> , 2011 , 185,	2.5	1
53	Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 693-700	2.5	22
52	The role of radical cystectomy in patients with clinical T4b bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 157-61	2.8	12
51	Enhanced recovery after surgery (ERAS) protocols: Time to change practice?. <i>Canadian Urological Association Journal</i> , 2011 , 5, 342-8	1.2	110
50	Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. <i>Supportive Care in Cancer</i> , 2011 , 19, 1117-24	3.9	8
49	Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. <i>Nutrition and Cancer</i> , 2011 , 63, 908-15	2.8	24
48	The Canadian Bladder Cancer Network: efforts to improve patient care. <i>Canadian Urological Association Journal</i> , 2011 , 5, 88	1.2	
47	Clinically significant urethral stricture and/or subclinical urethral stricture after high-intensity focused ultrasound correlates with disease-free survival in patients with localized prostate cancer. <i>Urologia Internationalis</i> , 2011 , 87, 276-81	1.9	8
46	From vision to reality: the origins of intraoperative MR imaging. <i>Acta Neurochirurgica Supplementum</i> , 2011 , 109, 3-7	1.7	12
45	Using clinical practice guidelines in our own backyard: treating our patients with bladder cancer. <i>Canadian Urological Association Journal</i> , 2010 , 4, 268	1.2	
44	Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. <i>BJU International</i> , 2010 , 106, 1799-804	5.6	31

43	Perioperative chemotherapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2009 , 3, S223-7	1.2	7
42	There is no role for focal therapy in prostate cancer. <i>Canadian Urological Association Journal</i> , 2009 , 3, 331-332	1.2	4
41	The impact of variant histology on the outcome of bladder cancer treated with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 3-7	2.8	176
40	Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. <i>Journal of Urology</i> , 2008 , 179, 353-8	2.5	66
39	Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?. <i>Journal of Urology</i> , 2008 , 180, 1146-53	2.5	4
38	Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. <i>Clinical Cancer Research</i> , 2008 , 14, 1478-86	12.9	85
37	Growth factors and receptors as prognostic markers in urothelial carcinoma. <i>Current Urology Reports</i> , 2008 , 9, 55-61	2.9	39
36	Considerations on the use of diagnostic markers in management of patients with bladder cancer. <i>World Journal of Urology</i> , 2008 , 26, 39-44	4	17
35	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1015-26	3.5	10
34	Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. <i>Journal of Urology</i> , 2007 , 177, 1900-6	2.5	16
33	Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2007 , 178, 2302-6; discussion 2307	2.5	112
32	Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. <i>Prostate</i> , 2007 , 67, 743-56	4.2	64
31	A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. <i>BJU International</i> , 2007 , 100, 63-9	5.6	7
30	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. <i>BJU International</i> , 2007 , 100, 1377-84	5.6	57
29	Re: Nomograms provide improved accuracy for predicting survival after radical cystectomy. <i>European Urology</i> , 2007 , 51, 1140-1	10.2	
28	Endogenous growth inhibition of angiogenesis in brain tumors. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 469-79	9.6	3
27	Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 623-34	9.6	95
26	Recovery kinetics of heart rate and oxygen uptake in long-term survivors of acute leukemia in childhood. <i>European Journal of Pediatrics</i> , 2007 , 166, 1135-42	4.1	5

25	Emerging drugs for targeted therapy of bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 435-48	3.7	5
24	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 277-85	6.1	56
23	Targeted therapies in bladder cancer--an update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 433-8	2.8	70
22	1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. <i>Journal of Urology</i> , 2007 , 177, 502-502	2.5	4
21	Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5528-35	2.2	62
20	Toward Real-Time Image Guided Neurosurgery Using Distributed and Grid Computing 2006 ,		22
19	Prostate cancer on the Internet--information or misinformation?. <i>Journal of Urology</i> , 2006 , 175, 1836-42; discussion 1842	2.5	56
18	Urethral and bladder neck injury associated with pelvic fracture in 25 female patients. <i>Journal of Urology</i> , 2006 , 175, 2140-4; discussion 2144	2.5	56
17	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?. <i>Current Opinion in Urology</i> , 2006 , 16, 344-9	2.8	22
16	Neoadjuvant chemotherapy for bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 531-42	4	24
15	Cystoprostatectomy and neobladder construction for florid cystitis glandularis. <i>Urology</i> , 2005 , 65, 174	1.6	14
14	Fournier's Gangrene 2005 , 157-168		
13	Meshed unexpanded split-thickness skin grafting for reconstruction of penile skin loss. <i>Journal of Urology</i> , 2004 , 172, 976-9	2.5	87
12	Hand-assisted laparoscopic right-donor nephrectomy in a patient with situs inversus. <i>Transplantation</i> , 2003 , 76, 1530	1.8	7
11	Extensive palliative surgery for advanced mesothelioma of the tunica vaginalis. <i>Urology</i> , 2003 , 62, 748	1.6	13
10	Cystoenteric conversion and reduction cystoplasty for treatment of bladder dysfunction after pancreas transplantation. <i>Journal of Urology</i> , 2003 , 170, 1913-7	2.5	9
9	Minimalist approach: functional mapping. <i>Clinical Neurosurgery</i> , 2002 , 49, 90-102		5
8	Regulation of secretion of PTHrP by Ca(2+)-sensing receptor in human astrocytes, astrocytomas, and meningiomas. <i>American Journal of Physiology - Cell Physiology</i> , 2000 , 279, C691-9	5.4	67

7	Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. <i>European Urology</i> , 2000 , 37 Suppl 3, 34-40	10.2	14
6	NEPHRON SPARING SURGERY FOR CENTRAL RENAL TUMORS: EXPERIENCE WITH 33 CASES. <i>Journal of Urology</i> , 2000 , 163, 737-743	2.5	53
5	RETRACTILE MESENTERITIS MIMICKING AN ADRENAL TUMOR. <i>Journal of Urology</i> , 1999 , 162, 1677-1678	2.5	
4	STRATEGIES FOR RECONSTRUCTION AFTER UNSUCCESSFUL OR UNSATISFACTORY PRIMARY TREATMENT OF PATIENTS WITH BLADDER EXSTROPHY OR INCONTINENT EPISPADIAS. <i>Journal of Urology</i> , 1999 , 161, 1934-1941	2.5	29
3	Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 495-505	6.2	46
2	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> ,	1	8
1	The consensus molecular classification of muscle-invasive bladder cancer		6